Chiasma Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Chiasma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CHMA, but not buy additional shares or sell existing shares.
View analyst ratings for Chiasma or view top-rated stocks.

Wall Street analysts have given Chiasma a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chiasma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Chiasma, Inc. (NASDAQ:CHMA) released its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.18. The biotechnology company earned $1.92 million during the quarter, compared to analyst estimates of $1.80 million.
View Chiasma's earnings history.

3 Wall Street analysts have issued 12 month price objectives for Chiasma's shares. Their forecasts range from $12.00 to $15.00. On average, they anticipate Chiasma's share price to reach $13.50 in the next year. This suggests a possible upside of 259.0% from the stock's current price.
View analysts' price targets for Chiasma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Chiasma include Design Therapeutics (DSGN), Gossamer Bio (GOSS), ADVANZ PHARMA (CXRXF), VBI Vaccines (VBIV), Dyne Therapeutics (DYN), Gracell Biotechnologies (GRCL), BioXcel Therapeutics (BTAI), Akero Therapeutics (AKRO), Shattuck Labs (STTK), Kiniksa Pharmaceuticals (KNSA), Crinetics Pharmaceuticals (CRNX), Annexon (ANNX), Ocular Therapeutix (OCUL), Celularity (CELU) and Cara Therapeutics (CARA).
View all of CHMA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals (GWPH), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Amarin (AMRN), Exelixis (EXEL) and Ovid Therapeutics (OVID).

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Chiasma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.08%), Man Group plc (3.39%), Highbridge Capital Management LLC (2.25%), Millennium Management LLC (2.23%), Bruce & Co. Inc. (2.16%) and BlackRock Inc. (2.12%). Company insiders that own Chiasma stock include David M Stack, Raj Kannan, Roni Mamluk and William Ludlam.
View institutional ownership trends for Chiasma.

CHMA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Ikarian Capital LLC, Vanguard Group Inc., Northern Trust Corp, Geode Capital Management LLC, Morgan Stanley, and Morgan Stanley.
View insider buying and selling activity for Chiasma or view top insider-selling stocks.

CHMA stock was purchased by a variety of institutional investors in the last quarter, including Man Group plc, Highbridge Capital Management LLC, Millennium Management LLC, Whitebox Advisors LLC, Yakira Capital Management Inc., Ergoteles LLC, Tudor Investment Corp Et Al, and Crabel Capital Management LLC. Company insiders that have bought Chiasma stock in the last two years include David M Stack, Raj Kannan, and William Ludlam.
View insider buying and selling activity for Chiasma or or view top insider-buying stocks.

One share of CHMA stock can currently be purchased for approximately $3.76.

Chiasma has a market capitalization of $217.68 million and generates $1.11 million in revenue each year. The biotechnology company earns $-74,780,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

Chiasma employs 85 workers across the globe.

The official website for Chiasma is www.chiasmapharma.com.

Chiasma is headquartered at 140 Kendrick Street Building C East, Needham MA, 02494.

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected].